Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim, 27 Nov 2019
The current standard of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour with a rapid disease course, consists of maximum safe surgical resection followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the evidence and shared their clinical experience on the use of tumour treating fields (TTFields), a novel treatment modality for GBM. 

Metastasis-directed therapy may reduce risk of death in HNSCC

30 Oct 2019

Metastasis-directed therapy (MDT) may confer significant benefit to patients with head and neck squamous cell carcinoma (HNSCC) with limited metastatic disease, suggests a recent study.

Of the 186 patients analysed, 30 (16.1 percent) underwent MDT. Five-year overall survival (OS) was higher among patients with a single metastasis (35 percent, 95 percent CI, 16–54 percent) than among those with multiple metastases (4 percent, 2–9 percent).

Multivariable analysis revealed that oral cavity (hazard ratio [HR], 2.22, 1.16–4.25; p=0.015) or sinonasal primary (HR, 4.88, 1.10–21.70; p=0.037) were associated with a higher risk of death. In contrast, treatment with MDT (HR, 0.36, 0.17–0.74; p=0.006) was associated with a lower risk of death.

Following MDT, median subsequent metastasis-free survival was estimated at 26.4 months (9.8–54.0 months) and 5-year survival was 31 percent (15–48 percent).

This study examined the outcomes of metastatic HNSCC by disease burden with an emphasis on MDT in patients with limited metastatic disease burden. A total of 186 patients who developed metastatic disease after definitive therapy for HNSCC were included.

The authors enumerated clinically and radiographically apparent metastases. They used Kaplan-Meier methods to estimate survival and Cox regression to evaluate the association between clinical variables.

“Prospective trials evaluating MDT in HNSCC are warranted,” the authors said.

Following first-line best systemic treatment, median survival for recurrent/metastatic HNSCC patients is around 10 months. [Future Oncol 2018;14:877-889]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim, 27 Nov 2019
The current standard of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour with a rapid disease course, consists of maximum safe surgical resection followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the evidence and shared their clinical experience on the use of tumour treating fields (TTFields), a novel treatment modality for GBM.